ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Enjaymo 50 mg/mL solution for infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each mL of solution for infusion contains 50 mg of sutimlimab*. One vial contains 1 100 mg of sutimlimab in 22 mL

* Sutimlimab is an immunoglobulin G4 (IgG4) monoclonal antibody (mAb) produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

Excipient with known effect

Each mL of solution for infusion contains 3.5 mg sodium

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for infusion (infusion)

Opalescent, colourless to slightly yellow solution essentially free of visible particles, with a pH of approximately 6.1 and osmolality of 268-312 mOsm/Kg.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).

4.2 Posology and method of administration

Enjaymo must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with haematological disorders.

Posology

Patients should be vaccinated according to the most current local recommendations for patients with persistent complement deficiencies (see section 4.4).

The recommended dose is based on body weight. For patients weighing 39 kg to less than 75 kg, the recommended dose is 6500 mg and for patients weighing 75 kg or more, the recommended dose is 7500 mg. Administer Enjaymo intravenously weekly for the first two weeks, with administration every two weeks thereafter. Enjaymo should be administered at the recommended dose regimen time points, or within two days of these time points (see section 4.4). Enjaymo is intended for continuous use as chronic therapy only, unless the discontinuation of Enjaymo is clinically indicated.
Missed dose

If a dose is missed, the missed dose should be administered as soon as possible. If the duration after the last dose exceeds 17 days, therapy should be reinitiated with weekly administrations for the first two weeks followed by administration every two weeks thereafter.

Special populations

Elderly
No dose adjustment is required for patients with CAD aged 65 years and over (see sections 5.1 and 5.2).

Hepatic impairment
No dose adjustment is required in patients with hepatic impairment.

Renal impairment
No dose adjustment is required in patients with renal impairment.

Paediatric population
There is no relevant use of Enjaymo in children < 18 years of age in the treatment of CAD.

Method of administration

Enjaymo is for intravenous infusion only. Do not administer as an intravenous push or bolus. For instructions on preparation and administration, see section 6.6.

Following preparation, Enjaymo infusion solution should be administered intravenously at the infusion rate presented in Table 1.

Table 1 - Infusion reference table

<table>
<thead>
<tr>
<th>Body weight range</th>
<th>Dose (mg)</th>
<th>Number of vials needed</th>
<th>Volume (mL)</th>
<th>Maximum infusion rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greater than or equal to 39 kg to less than 75 kg</td>
<td>6500</td>
<td>6</td>
<td>130</td>
<td>130 mL/hour</td>
</tr>
<tr>
<td>75 kg or greater</td>
<td>7500</td>
<td>7</td>
<td>150</td>
<td>150 mL/hour</td>
</tr>
</tbody>
</table>

Patients with cardiopulmonary disease may receive the infusion over 120 minutes.

If an adverse reaction occurs during the administration of Enjaymo, the infusion may be slowed or stopped at the discretion of the physician. If hypersensitivity reactions occur, discontinue Enjaymo and initiate appropriate treatment. Monitor the patient for at least two hours following completion of the initial infusion for signs or symptoms of an infusion and/or hypersensitivity reaction. Monitor the patient for one hour following completion of subsequent infusions for signs or symptoms of an infusion reaction.

Home infusion

Home infusions should be performed by a healthcare professional. The decision to consider home infusion should be based on individual clinical characteristics of the patient and individual needs of the patient. Transitioning the infusion from a clinical facility to home administration includes ensuring that adequate infrastructure and resourcing is in place and consistent with treating physician orders. Infusion of Enjaymo at home may be considered for patients who have tolerated their infusion well in a clinical facility and have not had infusion related reactions. A patient’s underlying co-morbidities and ability to adhere to the home infusion requirements need to
be considered when evaluating the patient for eligibility to receive home infusion. In addition, the following criteria should be considered:

- The patient must have no ongoing concurrent condition that, in the opinion of the physician, may place the patient at greater risk when receiving an infusion in the home setting rather than in the clinic setting. A comprehensive evaluation should be completed before the initiation of home infusion to ensure that the patient is medically stable.
- The patient must have successfully received Enjaymo infusion in a clinical setting (hospital or outpatient) for at least three months under the supervision of a physician or care provider experienced in the management of patients with CAD.
- The patient must be willing and able to comply with home infusion procedures and recommendations of the treating physician or care provider.
- The healthcare professional administering the infusion at home should be available at all times during the home infusion and for at least 1 hour after infusion.

If the patient experiences adverse reactions during the home infusion, the infusion process should be stopped immediately, appropriate medical treatment should be initiated (see section 4.4) and the treating physician should be notified. In such cases, the treating physician should decide if subsequent infusions should occur and if so, whether the infusions should be administered in a hospital or supervised outpatient care setting.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Infections

Enjaymo targets the classical complement pathway (CP) specifically binding to complement protein component 1, s subcomponent (C1s) preventing the cleavage of complement protein C4. Although the lectin and alternate pathways remain unaffected, patients may have an increased susceptibility to serious infections, especially infections caused by encapsulated bacteria such as *Neisseria meningitides*, *Streptococcus pneumoniae*, and *Haemophilus influenzae*. Patients should be vaccinated against encapsulated bacteria before treatment with Enjaymo is started, please see “Vaccinations” below.

In clinical studies with CAD, serious infections, including sepsis, have been reported in patients receiving treatment with Enjaymo (see section 4.8). Enjaymo should not be initiated in patients with active, serious infections. Patients should be monitored for early signs and symptoms of infections and should be informed to seek immediate medical care if such symptoms should occur.

Patients with viral hepatitis and HIV were excluded from the clinical studies. Before and during treatment, patients must notify their physician if they have been diagnosed with hepatitis B, hepatitis C, or HIV infection. Be cautious when treating patients with a history of hepatitis B, hepatitis C, or HIV infection.

Vaccinations

Vaccinate patients according to the most current local recommendations for patients with persistent complement deficiencies, including meningococcal and streptococcal vaccines. Revaccinate patients in accordance with local recommendations.
Immunize patients without a history of vaccination against encapsulated bacteria at least 2 weeks prior to receiving the first dose of Enjaymo. If urgent Enjaymo therapy is indicated in an unvaccinated patient, administer vaccine(s) as soon as possible. The benefits and risks of antibiotic prophylaxis for prevention of infections in patients receiving Enjaymo have not been established.

**Hypersensitivity reactions**

As with other protein products, administration of Enjaymo may result in hypersensitivity reactions, including anaphylaxis. In clinical studies, no serious hypersensitivity reactions were observed with Enjaymo. If hypersensitivity reactions occur, discontinue Enjaymo and initiate appropriate treatment.

**Infusion-related reactions**

Administration of Enjaymo may result in infusion-related reactions during the infusion or immediately after the infusion (see section 4.8). Patients should be monitored for infusion-related reactions, infusion interrupted if a reaction occurs and appropriate treatment initiated.

**Systemic lupus erythematosus (SLE)**

Individuals with inherited classical complement deficiency are at a higher risk for developing SLE. Patients with SLE were excluded from clinical studies with Enjaymo. Patients being treated with Enjaymo should be monitored for signs and symptoms of SLE and evaluated appropriately. Use Enjaymo with caution in patients with SLE or those who develop signs and symptoms of SLE.

**Monitoring CAD manifestations after Enjaymo discontinuation**

The effects on haemolysis diminish after end of treatment. Patients should therefore be monitored for signs and symptoms of haemolysis in case of treatment discontinuation.

**Sodium**

This medicinal product contains 3.5 mg per mL or 77 mg sodium per vial, equivalent to 3.85% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

**4.5 Interaction with other medicinal products and other forms of interaction**

No interaction studies have been performed. Enjaymo is an unlikely candidate for cytochrome P450 mediated drug-drug interactions as it is a recombinant human protein. The interaction of sutimlimab with substrates of CYPs has not been studied. However, sutimlimab decreases the levels of proinflammatory cytokines in patients, such as IL-6 which is known to suppress the expression of specific hepatic CYP450 enzymes (CYP1A2, CYP2C9, CYP2C19, and CYP3A4). Therefore, caution should be exercised when starting or discontinuing sutimlimab treatment in patients also receiving substrates of CYP450 3A4, 1A2, 2C9 or 2C19, particularly those with a narrow therapeutic index (such as warfarin, carbamazepine, phenytoin and theophylline), and doses adjusted if needed.

**4.6 Fertility, pregnancy and lactation**

**Pregnancy**

There are no available data on sutimlimab from the use in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).

Human IgG antibodies are known to cross the placental barrier; therefore, sutimlimab may be transmitted from the mother to the developing foetus.
As a precautionary measure, it is preferable to avoid the use of sutimlimab during pregnancy. Sutimlimab should be given during pregnancy only if clearly indicated.

**Breast-feeding**

Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short period. It is unknown whether sutimlimab/metabolites are excreted in human milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from sutimlimab therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

**Fertility**

Effects of sutimlimab on male and female fertility have not been studied in animals. In repeat-dose studies with sutimlimab with exposures at up to approximately 4 times the recommended human dose, no effects on reproductive organs were observed in cynomolgus monkeys.

**4.7 Effects on ability to drive and use machines**

Enjaymo has no or negligible influence on the ability to drive and use machines.

**4.8 Undesirable effects**

**Summary of safety profile**

The most frequently reported adverse reactions with Enjaymo in CADENZA and CARDINAL clinical studies were headache, hypertension, urinary tract infection, upper respiratory tract infection, nasopharyngitis, nausea, abdominal pain, infusion-related reactions and cyanosis (reported as acrocyanosis).

**Tabulated list of adverse reactions**

The safety evaluation of Enjaymo in patients with CAD was primarily based on data from 66 patients who participated in the phase 3, randomized, placebo-controlled study (CADENZA) and in an open-label single-arm study (CARDINAL).

Listed in Table 2 are adverse reactions observed in the CADENZA and CARDINAL studies presented by system organ class and frequency, using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

**Table 2 List of adverse reactions in CADENZA and CARDINAL studies**

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>Very common</th>
<th>Common</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Urinary tract infection&lt;br&gt;Cystitis&lt;br&gt;Upper respiratory tract infections&lt;sup&gt;a&lt;/sup&gt;&lt;br&gt;Nasopharyngitis&lt;sup&gt;b&lt;/sup&gt;&lt;br&gt;Gastroenteritis&lt;br&gt;Rhinitis</td>
<td>Lower respiratory tract infections&lt;sup&gt;c&lt;/sup&gt;&lt;br&gt;Urosepsis&lt;br&gt;Escherichia urinary tract infection&lt;br&gt;Urinary tract infection bacterial&lt;br&gt;Cystitis bacterial&lt;br&gt;Oral herpes&lt;br&gt;Herpes simplex viraemia&lt;br&gt;Herpes zoster</td>
</tr>
<tr>
<td>Disorder Type</td>
<td>Condition</td>
<td>Herpes simplex</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>--------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Pyrexia(^f) Feeling cold(^f) Infusion related reactions(^f)</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache</td>
<td>Aura(^f) Dizziness(^f)</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Hypertension(^d) Cyanosis (reported as acrocyanosis) Raynaud’s phenomenon</td>
<td>Hypotension(^f) Stress cardiomyopathy(^f)</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Abdominal pain(^c) Nausea</td>
<td>Diarrhoea(^f) Dyspepsia(^f) Aphthous ulcer(^f)</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td></td>
<td>Chest discomfort(^f)</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td>Pruritus(^f)</td>
</tr>
</tbody>
</table>

\(^{a}\)Upper respiratory tract infections: upper respiratory tract infection, bronchitis, and viral upper respiratory tract infection  
\(^{b}\)Nasopharyngitis: nasopharyngitis, pharyngitis  
\(^{c}\) Lower respiratory tract infections: pneumonia klebsiella, COVID-19 pneumonia, lower respiratory tract infection, respiratory tract infection viral, respiratory tract infection, pneumonia  
\(^{d}\)Hypertension: hypertension, blood pressure increased, essential hypertension, hypertensive crisis, white coat hypertension  
\(^{e}\)Abdominal pain: abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness  
\(^{f}\)Infusion related reaction: All occurred within 24 hours of start of Enjaymo infusion. *Events suggestive of hypersensitivity reactions are included in the table.

**Serious infections**

Of the 66 patients who participated in CADENZA and CARDINAL studies, serious infections were reported in 10 (15.2%) patients. Serious infections listed in the ADR table include respiratory tract infection [pneumonia klebsiella (n=1), respiratory tract infection (n=1), COVID-19 pneumonia (n=1)], urinary tract infection [urosepsis (n=1), urinary tract infection (n=1), urinary tract infection bacterial (n=1)], herpes zoster (n=1). Sutimlimab was discontinued in one patient due to a serious infection of Klebsiella pneumonia with fatal outcome. No other fatal events of infections were reported. See section 4.4 for information on vaccination recommendations for serious infections and for monitoring early signs and symptoms of infections.

**Immunogenicity**

Immunogenicity of sutimlimab was assessed in CAD patients in the CARDINAL and CADENZA studies at baseline, during the treatment period, and at end of treatment (Week 26). Two of the 24 patients (8.3%) enrolled in the CARDINAL study who received at least one dose of sutimlimab developed treatment-emergent ADAs. In CADENZA, 6 of 42 patients treated with sutimlimab (14.3%) developed treatment-emergent ADAs. These ADAs were transient in nature with low titre and were not associated with changes in the pharmacokinetic profile, clinical response, or adverse events.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
4.9 Overdose

In patients who experience overdose, immediate interruption of infusion and close monitoring is recommended.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants, ATC code: L04AA55

Mechanism of action

Sutimlimab is an IgG, subclass 4 (IgG4) monoclonal antibody (mAb) that inhibits the classical pathway (CP) and specifically binds to complement protein component 1, s subcomponent (C1s), a serine protease that cleaves C4. The activities of the lectin and alternative complement pathways are not inhibited by sutimlimab. Inhibition of the classical complement pathway at the level of C1s prevents deposition of complement opsonins on the surface of red blood cells, resulting in inhibition of haemolysis in patients with CAD, prevents generation of proinflammatory anaphylatoxins C3a and C5a and the downstream terminal complement complex C5b-9.

Clinical efficacy and safety

Greater than 90% inhibition of CP was observed after the first Enjaymo infusion and C4 levels were restored to normal levels (0.2 g/L) in CAD patients within one week following the first dose of Enjaymo.

The safety and efficacy of Enjaymo in patients with cold agglutinin disease (CAD) were assessed in a phase 3, randomized, double-blind, placebo-controlled study (CADENZA) in 42 patients (n=22 on Enjaymo and n=20 on placebo) and in a phase 3, open-label, single-arm study (CARDINAL) in 24 patients for a duration of 26 weeks. Following the completion of the six-month treatment periods (Part A), patients in both studies continued to receive Enjaymo in a long-term safety and durability of response extension phase (Part B) for an additional 12 months (CADENZA) and 24 months (CARDINAL) following last patient out from Part A. Both studies included a 9-week follow-up after the last dose of Enjaymo. Key eligibility criteria were a baseline haemoglobin (Hgb) ≤10 g/dL and active haemolysis with a bilirubin level above the normal reference range. Patients with cold agglutinin syndrome (CAS) were excluded. Patients in the CADENZA study did not have a history of transfusion within 6 months, or more than one blood transfusion in the 12 months prior to enrolment in the study while patients enrolled in the CARDINAL study had a history of at least one documented blood transfusion within 6 months prior to enrolment in the study. Patients were administered 6500 mg for 39–<75 kg or 7500 mg Enjaymo for ≥75 kg intravenously over approximately 60 minutes on Day 0, Day 7, and every 14 days thereafter. Major baseline characteristics of the study population are summarized in Table 3 below.

Table 3 - Baseline characteristics of patients included in the clinical studies

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Statistic</th>
<th>CADENZA</th>
<th>CARDINAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>Enjaymo</td>
<td>Enjaymo</td>
</tr>
<tr>
<td></td>
<td>N= 20</td>
<td>N=22</td>
<td>N=24</td>
</tr>
<tr>
<td>Age</td>
<td>Mean</td>
<td>68.2</td>
<td>65.3</td>
</tr>
<tr>
<td></td>
<td>Min, Max</td>
<td>51, 83</td>
<td>46, 88</td>
</tr>
<tr>
<td>Parameter</td>
<td>Statistic</td>
<td>CADENZA</td>
<td>CARDINAL</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------</td>
<td>------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo N= 20</td>
<td>Enjaymo N=22</td>
</tr>
<tr>
<td>Sex</td>
<td>n (%)</td>
<td>4 (20.0)</td>
<td>5 (22.7)</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td>16 (80.0)</td>
<td>17 (77.3)</td>
</tr>
<tr>
<td>Body weight</td>
<td>Mean, Kg</td>
<td>64.9</td>
<td>66.8</td>
</tr>
<tr>
<td></td>
<td>Min, Max</td>
<td>48, 95</td>
<td>39, 100</td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>Mean, g/dL</td>
<td>9.33</td>
<td>9.15</td>
</tr>
<tr>
<td>Bilirubin (total)*</td>
<td>µmol/L</td>
<td>35.77 (1.75 X ULN)</td>
<td>41.17 (2 X ULN)</td>
</tr>
<tr>
<td>History of transfusion</td>
<td>Mean number of transfusions (range)</td>
<td>0 (0, 1)</td>
<td>0 (0, 1)</td>
</tr>
<tr>
<td>Within last 6 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within last 12 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FACIT†-Fatigue scale</td>
<td>Mean</td>
<td>32.99</td>
<td>31.67</td>
</tr>
</tbody>
</table>

*N=21 in CARDINAL; Placebo N=18 and Enjaymo N= 20 in CADENZA, for bilirubin data excluding patients with either a positive or no available test result for Gilbert’s syndrome.
†ULN: Upper limit of normal, FACIT: Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue is measured on a scale of 0 (worst fatigue) to 52 (no fatigue))

**CADENZA Study**

Forty-two patients were randomized to receive Enjaymo (n=22); or placebo (n=20) through Week 25.

Efficacy was based on the proportion of patients who met the primary endpoint criteria: an increase from baseline in Hgb level ≥ 1.5 g/dL at the treatment assessment time point (mean value from Weeks 23, 25, and 26), no blood transfusion from Week 5 through Week 26, and no treatment for CAD beyond what was permitted per protocol from Week 5 through Week 26. A patient received a blood transfusion if they met the following haemoglobin threshold: Hgb < 7 g/dL or for a Hgb < 9 g/dL with symptoms. Prohibited therapies included rituximab alone or in combination with cytotoxic agents.

Efficacy was further assessed by the following two key secondary endpoints: based on the effect of Enjaymo on the mean change from baseline in Hgb and the FACIT-fatigue score to assess change in quality of life. Additional secondary endpoints were laboratory measures of haemolysis including mean change from baseline in total bilirubin. Supportive efficacy data collected included transfusion usage after five weeks of treatment.

Efficacy results are described in Tables 4 and 5 below.

**Table 4**- Efficacy results in patients with CAD in the CADENZA study - Part A
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Statistic</th>
<th>Placebo</th>
<th>Enjaymo</th>
<th>Treatment effect</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>N=20</td>
<td>N=22</td>
<td></td>
</tr>
<tr>
<td>Responder &lt;sup&gt;a&lt;/sup&gt;</td>
<td>%</td>
<td>3 (15.0)</td>
<td>16 (72.7)</td>
<td>15.94 (2.88, 88.04)</td>
</tr>
<tr>
<td></td>
<td>(95 % CI)</td>
<td>(3.2, 37.9)</td>
<td>(49.8, 89.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Odds Ratio</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(95 % CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p value</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>Mean change from baseline (LS† Mean), g/dL</td>
<td>0.09</td>
<td>2.66</td>
<td>2.56</td>
</tr>
<tr>
<td></td>
<td>95% CI of LS Mean</td>
<td>(-0.5, 0.68)</td>
<td>(2.09, 3.22)</td>
<td>(1.75, 3.38)</td>
</tr>
<tr>
<td></td>
<td>p value</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean number of transfusions</td>
<td>n (SD)</td>
<td>0.5 (1.1)</td>
<td>0.05 (0.2)</td>
<td>NC</td>
</tr>
<tr>
<td>(Week 5 to Week 26)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FACIT&lt;sup&gt;†&lt;/sup&gt;-Fatigue scale</td>
<td>Mean</td>
<td>33.66</td>
<td>43.15</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean change from baseline (LS† Mean)</td>
<td>1.91</td>
<td>10.83</td>
<td>8.93</td>
</tr>
<tr>
<td></td>
<td>95% CI of LS Mean</td>
<td>(-1.65, 5.46)</td>
<td>(7.45, 14.22)</td>
<td>(4, 13.85)</td>
</tr>
<tr>
<td></td>
<td>p value</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total bilirubin&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Mean, µmol/L</td>
<td>33.95</td>
<td>12.12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean change from baseline</td>
<td>-1.83</td>
<td>-22.13</td>
<td>NC</td>
</tr>
<tr>
<td></td>
<td>Number of patients normalized (%)</td>
<td>4 (22.2%)</td>
<td>15 (88.2%)</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>A responder was defined as a patient with an increase from baseline in Hgb level ≥ 1.5 g/dL at the treatment assessment time point (mean value from Weeks 23, 25, and 26), no blood transfusion from Week 5 through Week 26, and no treatment for CAD beyond what was permitted per protocol from Week 5 through Week 26.

<sup>*</sup>N=18 for placebo and N=17 for Enjaymo, for bilirubin data excluding patients with either a positive or no available test result for Gilbert’s syndrome

<sup>†</sup>LS: Least Square, FACIT: Functional Assessment of Chronic Illness Therapy, NC= Not calculated

Mean change from baseline in haemoglobin (Hgb) is shown in the Figure 1 below.
Mean bilirubin levels by visit is shown in the Figure 2 below.

Figure 2- CADENZA Study Part A: Plot of mean bilirubin (µmol/L) (+/- SE) by visit (excluding subjects with positive or unknown Gilbert’s syndrome test results)

Health-Related Quality of Life
In Part A, increases in mean FACIT-fatigue scores are presented in the Figure 3 below.

**Figure 3 – CADENZA Study Part A: Plot of mean change in FACIT-Fatigue score (SE) by visit – Observed – Full Analysis Set**

In Part B, mean haemoglobin levels were maintained >11 g/dL and sustained normalization of mean bilirubin levels were observed indicating a sustained decrease in haemolysis. Improvements in FACIT-Fatigue score observed in Part A were maintained.

After the last dose of Enjaymo in the study, signs and symptoms of recurrent haemolysis were observed. Mean haemoglobin, nine weeks after the last dose in Part B, decreased by 2.41 g/dL standard deviation (SD: 2.21) and mean bilirubin increased by 21.80 µmol/L (SD:18.14) from the last available values during treatment. The mean FACIT-Fatigue score returned to near baseline levels at 31.29, with a mean SD change from baseline of -1.40 (11.48).

**CARDINAL Study**

Twenty-four patients were administered Enjaymo through Week 25.

Efficacy was based on the proportion of patients who met the primary endpoint criteria: an increase from baseline in Hgb level ≥ 2 g/dL or a Hgb level ≥ 12 g/dL at the treatment assessment time point (mean value from Weeks 23, 25, and 26), no blood transfusion from Week 5 through Week 26, and no treatment for CAD beyond what was permitted per protocol from Week 5 through Week 26. A patient received a blood transfusion if they met the following haemoglobin threshold: Hgb < 7 g/dL or for a Hgb < 9 g/dL with symptoms. Prohibited therapies included rituximab alone or in combination with cytotoxic agents.

Efficacy was further assessed by the following secondary endpoints: based on the effect of Enjaymo on Hgb and laboratory measures of haemolysis including mean change from baseline in total bilirubin. Change in quality of life was assessed by mean change from baseline in the FACIT-fatigue score as a secondary endpoint. Supportive efficacy data collected included transfusion usage after five weeks of treatment.
Table 5 presents efficacy results in patients with CAD in the CARDINAL study.

**Table 5 - Efficacy Results in Patients with CAD in the CARDINAL Study - Part A**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Statistic</th>
<th>ENJAYMO N=24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Responder&lt;sup&gt;a&lt;/sup&gt;</td>
<td>n (%)</td>
<td>13 (54)</td>
</tr>
<tr>
<td><strong>Haemoglobin</strong></td>
<td>Mean change from baseline (LS† Mean), g/dL</td>
<td>2.60</td>
</tr>
<tr>
<td></td>
<td>95% CI of LS Mean</td>
<td>(0.74, 4.46)</td>
</tr>
<tr>
<td><strong>Mean number of transfusions (Week 5 to Week 26)</strong></td>
<td>n</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>Total bilirubin</strong></td>
<td>Mean, µmol/L</td>
<td>15.48 (0.76 × ULN†)</td>
</tr>
<tr>
<td></td>
<td>Mean change from baseline (LS† Mean)</td>
<td>-38.18</td>
</tr>
<tr>
<td></td>
<td>Number of patients normalized (%)</td>
<td>13 (54.2)</td>
</tr>
<tr>
<td><strong>FACIT&lt;sup&gt;†&lt;/sup&gt;-Fatigue Scale</strong></td>
<td>Mean</td>
<td>44.26</td>
</tr>
<tr>
<td></td>
<td>Mean change from baseline (LS† Mean)</td>
<td>10.85</td>
</tr>
<tr>
<td></td>
<td>95% CI of LS Mean</td>
<td>(8.0, 13.7)</td>
</tr>
</tbody>
</table>

<sup>a</sup>A responder was defined as a patient with an increase from baseline in Hgb level ≥ 2 g/dL or a Hgb level ≥ 12 g/dL at the treatment assessment time point (mean value from Weeks 23, 25, and 26), no blood transfusion from Week 5 through Week 26, and no treatment for CAD beyond what was permitted per protocol from Week 5 through Week 26.

<sup>†</sup>N=21 for bilirubin data excluding patients with Gilbert’s syndrome

In Part B, mean haemoglobin levels were maintained >11 g/dL and sustained normalization of mean bilirubin levels were observed indicating a sustained decrease in haemolysis.

After the last dose of Enjaymo in the study, signs and symptoms of recurrent haemolysis were observed. Mean haemoglobin, nine weeks after the last dose in Part B, decreased by 2.28 g/dL (SD: 1.80) and mean bilirubin increased by 24.27 µmol/L (SD: 13.51) from the last available values during treatment. Mean FACIT-Fatigue scores returned towards baseline, with a mean SD change from baseline pre-treatment values of 1.05 (8.15).

**Paediatric population**

The European Medicines Agency has waived the obligation to submit the results of studies with Enjaymo in all subsets of the paediatric population in the treatment of primary Cold Agglutinin Disease (see section 4.2 for information on paediatric use).

**Elderly population**

Majority of the patients (43/66, 65%) included in the clinical studies with Enjaymo for CAD were 65 years of age or older. Reported clinical experience has not identified any differences in responses between those over the age of 65 and younger patients.

**5.2 Pharmacokinetic properties**

The pharmacokinetics (PK) of sutimlimab were characterized in 24 patients (CARDINAL) and 42 patients (CADENZA), which included 51 patients treated with 6500 mg and 15 patients with
7500 mg as per recommended posology. The total exposures at steady-state of proposed dosing regimen are presented in Table 6.

**Table 6 - Mean (SD) steady state exposure parameters**

<table>
<thead>
<tr>
<th>CARDINAL and CADENZA</th>
<th>Dose (mg)</th>
<th>C_{min} (µg/mL)*</th>
<th>AUC_{ss} (µg·h/mL)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6500 (n=51)</td>
<td>1397 (721)</td>
<td>697449 (256234)</td>
<td></td>
</tr>
<tr>
<td>7500 (n=15)</td>
<td>1107 (661)</td>
<td>576017 (253776)</td>
<td></td>
</tr>
</tbody>
</table>

* Abbreviations: AUC_{ss} = area under the curve between 2 consecutive doses after steady state is achieved; C_{min} = trough concentration at steady state defined as 1 hour prior to next dose administration

Steady state was achieved by week 7 after starting sutimlimab treatment, with accumulation ratio of less than 2.

**Distribution**

The volume of distribution at steady state in central and peripheral compartments was approximately 5.8 L in patients with CAD.

**Biotransformation**

Sutimlimab is a protein. It is generally recognized that antibodies are metabolized by degradation into small peptides and individual amino acids.

**Elimination**

The half-life of sutimlimab is dependent on the plasma concentration. The terminal elimination half-life of sutimlimab at steady-state based on the total clearance (linear and non-linear clearance) is 16 days.

**Linearity/non-linearity**

Following single doses, sutimlimab clearance showed a steep initial decrease at doses less than 30 mg/kg (~ 2 g), becoming independent of dose between 60 and 100 mg/kg of sutimlimab.

**Special populations**

No clinically significant differences were observed in the pharmacokinetics of sutimlimab based on sex, age, hepatic impairment, or renal impairment. Exposure levels (C_{max}, C_{min} and AUC) at steady state were estimated based on 6500 mg (<75 kg) and 7500 mg (>= 75 kg) given Days 0, 7 and every 14 days thereafter. The population pharmacokinetic analysis showed similar exposure parameters between sexes with 101 male and 95 female participants.

The population pharmacokinetic analysis showed similar exposure parameters with participant’s race (94 White, 10 Black, 42 Asian).

Population pharmacokinetic analysis showed that body weight and ethnicity (Japanese versus non-Japanese) influenced the pharmacokinetics of sutimlimab. Lower exposure was observed in participants with higher body weight. Based on cross-study comparison, sutimlimab AUC_{0-168} after 30 to 100 mg/kg was up to 38% higher in Japanese subjects than in non-Japanese participants.

**Pharmacokinetic/pharmacodynamic relationship(s)**
Sutimlimab concentration above 100 µg/mL resulted in maximal CP inhibition. The proposed dosing regimen resulted in adequate sutimlimab exposure at steady state to provide clinically relevant effects on Hgb, bilirubin, and total C4 levels.

5.3 Preclinical safety data

An enhanced pre- and post-natal development (ePPND) study in cynomolgus monkeys revealed no evidence of adverse developmental outcomes with intravenous administration of sutimlimab during organogenesis through delivery, at exposures approximately 2-3 times the AUC in humans at the maximum recommended dose. In repeat-dose studies with sutimlimab with exposures at up to approximately 4 times the recommended human dose, no effects on reproductive organs were observed in cynomolgus monkeys.

No animal studies have been conducted to evaluate the carcinogenic potential of sutimlimab.

Non-clinical data revealed no special hazard for humans based on nonclinical studies in cynomolgus monkeys.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Polysorbate 80 (E 433)
Sodium chloride
Sodium phosphate dibasic (E 339)
Sodium phosphate monobasic (E 339)
Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

Unopened vial:
3 years

Storage of the medicinal product after opening:

Chemical and physical in-use stability has been demonstrated for 16 hours at 18°C to 25°C or for 72 hours at 2°C to 8°C. From a microbiological point of view, the product should be used immediately.

If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not normally be for longer than 24 hours at 2°C to 8°C or 8 hours at room temperature, unless vial opening and pooling into the infusion bag has taken place in controlled and validated aseptic conditions.

6.4 Special precautions for storage

Store in a refrigerator (2°C-8°C).
Store in the original carton in order to protect from light.
Do not freeze.

For storage conditions after first opening of the medicinal product vial, see section 6.3.
6.5 Nature and contents of container

22 mL solution in vial (type I glass) with a stopper (butyl rubber), seal (aluminium) and a flip-off cap

Each pack contains 1 or 6 vials.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Enjaymo is provided as a solution in a single-dose vial and should be prepared by a healthcare professional using aseptic technique.

Preparation

1. Remove Enjaymo from the refrigerator. To minimize foaming, do not shake.
2. Inspect vials visually for particulate matter and discoloration prior to administration. The solution is an opalescent and colourless to slightly yellow liquid. Do not administer if discoloured or if other foreign particulate matter is present.
3. Withdraw the calculated volume from the appropriate number of vials based on the recommended dose (see Table 1) and add to an empty infusion bag. Discard unused portion remaining in the vial.
4. The prepared solution should be administered immediately. For storage conditions, see section 6.3.

Administration

1. Prior to administration, allow the infusion solution to adjust to room temperature (18°C-25°C). Refer to Table 1 for infusion rate, see section 4.2. The infusion should be administered over 1-2 hours depending on the patient’s body weight. Administer the infusion only through a 0.22-micron filter with a polyethersulfone (PES) membrane. Infusion warmers may be used, do not exceed a temperature of 40°C.
2. The infusion catheter and tubing should be primed with the dosing solution immediately before infusion and flushed immediately following completion of the infusion with enough quantity (approximately 20 mL) of sodium chloride 9 mg/mL (0.9%) solution for injection.
3. No incompatibilities have been observed between Enjaymo infusion solution and infusion bags made of Di-(2-ethylhexyl)phthalate (DEHP) plasticized polyvinyl chloride (PVC), Ethyl Vinyl Acetate (EVA) and polyolefin (PO); administration sets made of DEHP-plasticized PVC, DEHP-free polypropylene (PP) and polyethylene (PE); and vial adapters made of polycarbonate (PC) and acrylonitrile-butadiene-styrene (ABS).

7. MARKETING AUTHORISATION HOLDER

Sanofi B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands

8. MARKETING AUTHORISATION NUMBERS

EU/1/22/1687/001
EU/1/22/1687/002
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 15 November 2022

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
ANNEX II

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

Biogen Inc.
5000 Davis Drive
Research Triangle Park, NC 27709
USA

Name and address of the manufacturer responsible for batch release

Sanofi-Aventis Deutschland GmbH
Brüningstr. 50
Frankfurt am Main, 65926
Germany

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

• Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

• Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

• At the request of the European Medicines Agency;
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
• **Additional risk minimisation measures**

The MAH shall ensure that in each member state where Enjaymo is marketed, all healthcare professionals (HCPs) who are expected to prescribe Enjaymo are provided with the following educational materials:

- Physician’s guide
- Patient’s guide

These tools will convey key safety messages on the important identified risk of serious infections and important potential risk of meningococcal infections.

For Physician’s guide:
- Educate physicians that patients should be vaccinated (according to most current local vaccination guidelines for vaccine use in patients with persistent complement deficiencies) prior to initiating Enjaymo.
- Recommend on-treatment monitoring for early signs and symptoms of infection.
- Recommend individualized patient counselling.

For Patient’s guide:
- Enhance awareness of increased risk of infection and the need for vaccination.
- Enhance awareness of early signs and symptoms of infections and the need to seek immediate medical attention should they occur.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</th>
</tr>
</thead>
<tbody>
<tr>
<td>OUTER CARTON</td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT**

   Enjaymo 50 mg/mL solution for infusion
   sutimlimab

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each vial contains 1 100 mg of sutimlimab in 22 mL.

3. **LIST OF EXCIPIENTS**

   Excipients: Polysorbate 80, sodium chloride, sodium phosphate dibasic, sodium phosphate monobasic, water for injections.

4. **PHARMACEUTICAL FORM AND CONTENTS**

   Solution for infusion
   50 mg/mL
   1 vial
   6 vials

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Intravenous use.
   Read the package leaflet before use.

   For more information, scan QR code or visit [www.enjaymo.info.sanofi](http://www.enjaymo.info.sanofi)

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

   Do not shake

8. **EXPIRY DATE**

   EXP
9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze.
Store in the original carton in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Sanofi B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/22/1687/001
EU/1/22/1687/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted.

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING**

**IMMEDIATE LABEL: VIAL/GLASS**

1. **NAME OF THE MEDICINAL PRODUCT**

   Enjaymo 50 mg/mL infusion
   sutimlimab

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each vial contains 1 100 mg of sutimlimab in 22 mL

3. **LIST OF EXCIPIENTS**

   Excipients: Polysorbate 80 (E 433), sodium chloride, sodium phosphate dibasic (E 339), sodium phosphate monobasic (E 339), water for injections.

4. **PHARMACEUTICAL FORM AND CONTENTS**

   Solution for infusion
   50 mg/mL

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   IV
   Read the package leaflet before use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

   Do not shake

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**

   Store in a refrigerator. Do not freeze.
   Store in the original carton in order to protect from light.
| 10. | SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE |
| 11. | NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER |
|     | Sanofi B.V. |
| 12. | MARKETING AUTHORISATION NUMBER(S) |
| 13. | BATCH NUMBER |
|     | Lot |
B. PACKAGE LEAFLET
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully, before you are given this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Enjaymo is and what it is used for
2. What you need to know before you are given Enjaymo
3. How Enjaymo will be given
4. Possible side effects
5. How to store Enjaymo
6. Contents of the pack and other information

1. What Enjaymo is and what it is used for

Enjaymo contains the active substance sutimlimab and belongs to a class of medicines called monoclonal antibodies.

In the rare blood disorder cold agglutinin disease (CAD), certain antibodies of the immune defence system bind to red blood cells. This causes breakdown of the red blood cells (haemolytic anaemia) through activation of classical complement pathway (part of the immune defense system). Enjaymo blocks the activation of this part of the immune defence system.

Enjaymo is used to treat haemolytic anaemia in adults who have CAD. This reduces anaemia and lessen fatigue.

2. What you need to know before you are given Enjaymo

You must not receive Enjaymo
- if you are allergic to sutimlimab or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions
Talk to your doctor before you are given Enjaymo.

Infections

Inform your doctor if you have any infection including an ongoing infection such as HIV, hepatitis, B or hepatitis C or if you have a decreased ability to fight infections.

Vaccinations
Check with your doctor that you are appropriately vaccinated, and also have received meningococcal and streptococcal vaccines.

It is recommended that you are vaccinated at least 2 weeks before beginning Enjaymo. You need to be aware that vaccination may not always prevent these types of infection. Immediately contact your doctor if any signs of infection appear, see section 4 “Possible side effects”.

Allergic reactions

Seek medical help immediately if you notice any signs of an allergic reaction while or after you are given this medicine. For symptoms, see section 4 “Possible side effects”.

Infusion-related reactions

You may experience infusion-related reactions during the infusion or immediately after the infusion. Inform your healthcare professional immediately if you experience symptoms associated with Enjaymo infusion. For symptoms, see section 4 “Possible side effects”.

Systemic lupus erythematosus (SLE)

Inform your doctor if you have an autoimmune disease such as systemic lupus erythematosus (SLE), also known as lupus. Seek medical attention if you develop any symptoms of SLE such as joint pain or swelling, rash on the cheeks and nose or unexplained fever.

Children and adolescents

Enjaymo should not be used in children and adolescents under 18 years of age as CAD generally does not occur in this age group.

Other medicines and Enjaymo

Tell your doctor if you are taking, have recently taken or might take any other medicines.

Pregnancy and breast-feeding

Pregnancy

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before being given this medicine. It is not known if Enjaymo will affect your unborn baby. If you are pregnant, you should only be given Enjaymo if your doctor has clearly recommended it.

Breast-feeding

It is not known whether Enjaymo passes into breast milk. If you are breastfeeding or planning to breastfeed, talk to your doctor before using this medicine, so you and your doctor must decide if you should breast feed or if you will be given Enjaymo.

Driving and using machines

This medicine has no or negligible influence on the ability to drive and use machines.

Enjaymo contains sodium

This medicine contains 3.5 mg per mL or 77 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 3.85% of the recommended maximum daily dietary intake of sodium for an adult.
3. **How Enjaymo will be given**

Enjaymo will be given to you by a healthcare professional. It is given as an infusion (drip) into a vein (intravenously). The dose you will be given will depend on your body weight.

The infusion takes usually 1 to 2 hours. After each infusion you will be monitored for allergic reactions: after the first infusion you will be monitored for at least 2 hours. After the subsequent infusions you will be monitored for at least 1 hour.

You will usually receive:
- an initial dose of Enjaymo
- a dose of Enjaymo one week later
- thereafter you will start to receive Enjaymo every 2 weeks

**Home infusion**

- You will receive Enjaymo for at least three months at a health care facility.
- After this, your doctor may consider that you can have home infusion of Enjaymo.
- Home infusion will be performed by a health care professional.

**If you are given more Enjaymo than you should**

This medicine will be given by a healthcare professional. If you think that you have been accidentally given too much Enjaymo, please contact your doctor for advice.

**If you forget to use Enjaymo**

If you miss an appointment to receive Enjaymo, contact your doctor right away to reschedule your infusion.

**If you stop using Enjaymo**

The effects of Enjaymo will be reduced after end of the treatment. If you stop receiving Enjaymo, your doctor should check for return of signs and symptoms of CAD. The symptoms are caused by breakdown of your red blood cells and may include tiredness, shortness of breath, rapid heart rate or dark urine.

If you have any further questions on the use of this medicine, ask your doctor.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Immediately tell your health care professional giving you Enjaymo if you notice any signs of an allergic reaction while or shortly after you are given this medicine.** The signs may include:
- difficulty breathing or swallowing
- swelling of the face, lips, tongue or throat
- severe itching of the skin, with a red rash or raised bumps
- feeling faint.

If any of these symptoms occur during infusion, the infusion should be stopped immediately.

**Immediately tell your health care professional giving you Enjaymo if you notice any signs of a reaction related to the infusion while you are given this medicine.** Common (may affect up to 1 in 10 people). The signs may include:
- nausea
- feeling flushed
- headache
• shortness of breath
• rapid heart rate.

Tell your doctor as soon as possible if you experience symptoms or signs of an infection such as:
• fever with or without rash, chills, flu-like symptoms, cough/difficulty breathing, headache with nausea, vomiting, stiff neck, stiff back, confusion, eye sensitivity to light, pain during urination or urinating more often.
• Infections: urinary tract, upper respiratory tract, stomach and intestine, common cold, runny nose are very common (may affect more than 1 in 10 people).
• Infections: lower respiratory tract, urinary tract, herpes infection are common (may affect up to 1 in 10 people).

Tell your doctor or nurse if you get any of the following other side effects:

Very common (may affect more than 1 in 10 people)
• headache
• high blood pressure
• poor circulation with skin discoloration in hands and feet in response to cold and stress (Raynaud’s phenomenon, acrocyanosis)
• belly pain
• nausea

Common (may affect up to 1 in 10 people):
• Infusion related reactions
• Fever
• Feeling cold
• Dizziness
• Aura
• Low blood pressure
• Diarrhoea
• Stomach discomfort
• Mouth ulcer (aphthous ulcer)
• Chest discomfort
• Itching

Reporting of side effects
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Enjaymo

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and the carton after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C-8°C). Do not freeze.

Store in the original carton in order to protect from light.
Enjaymo should not be thrown away via wastewater or household waste. Your healthcare professional is responsible for disposing of any unused product correctly. This measure will help protect the environment.

6. Contents of the pack and other information

What Enjaymo contains
- The active substance is sutimlimab. Each vial of 22 mL solution contains 1100 mg of sutimlimab
- The other ingredients are polysorbate 80 (E 433), sodium chloride, sodium phosphate dibasic (E 339), sodium phosphate monobasic (E 339), and water for injections.

This medicine contains sodium (see section 2 “Enjaymo contains sodium”).

What Enjaymo looks like and contents of the pack

Enjaymo is an opalescent, colourless to slightly yellow solution for infusion, essentially free from particles.

Each pack contains 1 or 6 vials.

Not all pack sizes may be marketed.

Marketing Authorisation Holder
Sanofi B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands

Manufacturer
Sanofi-Aventis Deutschland GmbH
Brüningstr. 50
Frankfurt am Main, 65926
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
Sanoﬁ Belgium
Tél/Tel: +32 (0)2 710 54 00

Lietuva
Swixx Biopharma UAB
Tel: +370 5 236 91 40

България
Swixx Biopharma EOOD
Тел.: +359 (0)2 4942 480

Luxembourg/Luxemburg
Sanoﬁ Belgium
Tél/Tel: +32 (0)2 710 54 00 (Belgique/Belgien)

Česká republika
sanoﬁ-aventis, s.r.o.
Tel: +420 233 086 111

Magyarország
SANOFI-AVENTIS Zrt.
Tel: +36 1 505 0050

Danmark
Sanoﬁ A/S
Tlf: +45 45 16 70 00

Malta
Sanoﬁ S.r.l.
Tel: +39 02 39394275
Deutschland
Sanofi-Aventis Deutschland GmbH
Tel.: 0800 04 36 996
Tel. aus dem Ausland: +49 69 305 70 13

Eesti
Swixx Biopharma OÜ
Tel: +372 640 10 30

Ελλάδα
Sanofi-Aventis Μονοπρόσωπη ΑΕΒΕ
Τηλ: +30 210 900 16 00

España
sanofi-aventis, S.A.
Tel: +34 93 485 94 00

France
Sanofi Winthrop Industrie
Tel: 0 800 222 555
Appel depuis l’étranger: +33 1 57 63 23 23

Hrvatska
Swixx Biopharma d.o.o.
Tel: +385 1 2078 500

Ireland
sanofi-aventis Ireland Ltd. T/A SANOFI
Tel: +353 (0) 1 403 56 00

Ísland
Vistor hf.
Sími: +354 535 7000

Italia
Sanofi S.r.l.
Tel: 800 536 389

Κύπρος
C.A. Papaellinas Ltd.
Τηλ: +357 22 741741

Latvija
Swixx Biopharma SIA
Tel: +371 6 616 47 50

Nederland
Sanofi B.V.
Tel: +31 20 245 4000

Norge
sanofi-aventis Norge AS
Tlf: +47 67 10 71 00

Österreich
sanofi-aventis GmbH
Tel: +43 1 80 185 – 0

Polska
sanofi-aventis Sp. z o.o.
Tel.: +48 22 80 00 00

Portugal
Sanofi - Produtos Farmacêuticos, Lda
Tel: +351 21 35 89 400

România
Sanofi Romania SRL
Tel: +40 (0) 21 317 31 36

Slovenija
Swixx Biopharma d.o.o.
Tel: +386 1 235 51 00

Slovenská republika
Swixx Biopharma s.r.o.
Tel: +421 2 208 33 600

Suomi/Finland
Sanofi Oy
Puh/Tel: +358 (0) 201 200 300

Sverige
Sanofi AB
Tel: +46 (0)8 634 50 00

United Kingdom (Northern Ireland)
sanofi-aventis Ireland Ltd. T/A SANOFI
Tel: +44 (0) 800 035 2525

This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.
The following information is intended for healthcare professionals only:

**Traceability**
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

**Preparation**
Enjaymo is provided as a solution in a single-dose vial and should be prepared by a healthcare professional using aseptic technique.
1. Remove Enjaymo from the refrigerator. To minimize foaming, do not shake.
2. Inspect vials visually for particulate matter and discoloration prior to administration. The solution is an opalescent and colourless to slightly yellow liquid. Do not administer if discoloured or if other foreign particulate matter is present.
3. Withdraw the calculated volume from the appropriate number of vials based on the recommended dose (see Table 1 for the infusion reference) and add to an empty infusion bag. Discard any unused portion remaining in the vial.
4. The prepared solution should be administered immediately.

**Administration**
1. Prior to administration, allow the infusion solution to adjust to room temperature (18°C-25°C). Refer to Table 1 for infusion rate. The infusion should be administered over 1-2 hours depending on the patient’s body weight. Administer the infusion only through a 0.22-micron filter with a polyethersulfone (PES) membrane. Infusion warmers may be used, do not exceed a temperature of 40°C.
2. The infusion catheter and tubing should be primed with the dosing solution immediately before infusion and flushed immediately following completion of the infusion with enough quantity (approximately 20 mL) of sodium chloride 9 mg/mL (0.9%) solution for injection.
3. No incompatibilities have been observed between Enjaymo infusion solution and infusion bags made of Di-(2-ethylhexyl)phthalate (DEHP) plasticized polyvinyl chloride (PVC), Ethyl Vinyl Acetate (EVA) and polyolefin (PO); administration sets made of DEHP-plasticized PVC, DEHP-free polypropylene (PP) and polyethylene (PE); and vial adapters made of polycarbonate (PC) and acrylonitrile-butadiene-styrene (ABS).

**Table 1 - Infusion reference table**

<table>
<thead>
<tr>
<th>Body weight range</th>
<th>Dose (mg)</th>
<th>Number of vials needed</th>
<th>Volume (mL)</th>
<th>Maximum infusion rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greater than or equal to 39 kg to less than 75 kg</td>
<td>6500</td>
<td>6</td>
<td>130</td>
<td>130 mL/hour</td>
</tr>
<tr>
<td>75 kg or greater</td>
<td>7500</td>
<td>7</td>
<td>150</td>
<td>150 mL/hour</td>
</tr>
</tbody>
</table>

**Storage conditions**

*Unopened vial*
- Store in a refrigerator (2°C-8°C). Do not freeze.
- Store in the original carton in order to protect from light.

*After opening*
Chemical and physical in-use stability has been demonstrated for 16 hours at 18°C to 25°C or for 72 hours at 2°C to 8°C. From a microbiological point of view, the product should be used immediately.

If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not normally be for longer than 24 hours at 2°C to 8°C or 8 hours at room temperature, unless vial opening and pooling into the infusion bag has taken place in controlled and validated aseptic conditions.

**Home infusion**

Home infusions should be performed by a healthcare professional. The decision to consider home infusion should be based on individual clinical characteristics of the patient and individual needs of the patient. Transitioning the infusion from a clinical facility to home administration includes ensuring that adequate infrastructure and resourcing is in place and consistent with treating physician orders. Infusion of Enjaymo at home may be considered for patients who have tolerated their infusion well in a clinical facility and have not had infusion related reactions. A patient’s underlying co-morbidities and ability to adhere to the home infusion requirements need to be considered when evaluating the patient for eligibility to receive home infusion. In addition, the following criteria should be considered:

- The patient must have no ongoing concurrent condition that, in the opinion of the physician, may place the patient at greater risk when receiving an infusion in the home setting rather than in the clinic setting. A comprehensive evaluation should be completed before the initiation of home infusion to ensure that the patient is medically stable.
- The patient must have successfully received Enjaymo infusion in a clinical setting (hospital or outpatient) for at least three months under the supervision of a physician or care provider experienced in the management of patients with CAD.
- The patient must be willing and able to comply with home infusion procedures and recommendations of the treating physician or care provider.
- The healthcare professional administering the infusion at home should be available at all times during the home infusion and for at least 1 hour after infusion.

If the patient experiences adverse reactions during the home infusion, the infusion process should be stopped immediately, appropriate medical treatment should be initiated and the treating physician should be notified. In such cases, the treating physician should decide if subsequent infusions should occur and if so, whether the infusions should be administered in a hospital or supervised outpatient care setting.